Rheumatology

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

The approval makes methotrexate, currently, the only only oral liquid methotrexate on the market approved for both adult and pediatric indications.

Approval is based on a study in 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors.

Infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA.

An 11-year-old boy with a history of asthma and allergic rhinitis presented to the emergency department (ED) with worsening fatigue, minimal responsivity to external stimuli, and diffuse muscle weakness for 2 months.

Current treatment is primarily supportive care consisting of increased fluid intake to dilute oxalate in the urine, along with pyridoxine, or vitamin B6, to reduce oxalate production.

Jon Matthew Farber, MD, offers quick thoughts on a recent study regarding bone health and activity among adolescents withJIA.

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

pJIA can lead to an increased risk of permanent joint damage as well as delayed growth and development.

Additionally, a new weight-based oral solution, RINVOQ LQ, is now available as an option for the pediatric populations.

Psoriatic arthritis and spondyloarthritis occurred earlier in children and adolescents with IBD than in the matched references without IBD.

Tocilizumab-bavi (Tofidence; Biogen) demonstrated a biosimilarity to tocilizumab (Actemra; Genentech) based on multifaceted clinical and non-clinical data for polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (sJIA) in children aged 2 years and up. This makes it the first tocilizumab biosimilar to be FDA-approved in the United States, according to Biogen.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

A new study revealed no significant relationship between patients with juvenile idiopathic arthritis and exposure to maternal infection, however, investigators said that suggestive evidence of differential sex-specific results indicate a need for further study.

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

Laboratory tests are not very helpful when trying to determine whether a child with musculoskeletal complaints has any of the rheumatic diseases of childhood, and using adult models to evaluate these children is equally ineffective.

ABSTRACT: Dramatic progress has been made in our understanding of pediatric rheumatic disease. Various classification systems help identify juvenile idiopathic arthritis (JIA), which involves unique considerations that distinguish it from rheumatoid arthritis in adults. Vaccination issues are important for children with JIA. Renal involvement with systemic lupus erythematosus (SLE) is more common and more severe in children than in adults, but treatment of children who have SLE is similar to that of adults. Neonatal lupus erythematosus may occur in infants whose mothers have SLE. Juvenile dermatomyositis is associated with significant morbidity and mortality. Kawasaki disease is a common vasculitis of childhood, especially in infants and toddlers. Each of at least 8 major familial periodic fever clinical syndromes has specific distinguishing characteristics.